the sun malaysia ipaper logo 150x150
Friday, July 3, 2026
27.5 C
Kuala Lumpur
the sun malaysia ipaper logo 150x150

Tomei’s 9MFYE2023 exceeds pre-pandemic full year earnings

KUALA LUMPUR: For third quarter results for financial year ending Dec 31, 2023, integrated gold jewellery manufacturer and retailer Tomei Consolidated Berhad announced that the Group delivered a profit before tax (PBT) and profit after tax (PAT) of RM15.3 million and RM10.8 million respectively, on the back of a revenue of RM203.5 million.

For the nine months ended Sept 30, 2023 (9MFYE2023), revenue was RM664.6 million, with PBT and PAT of RM55.4 million and RM41.3 million respectively.

The results fundamentally reflected the Group’s strong performance which has more than normalised compared to pre-pandemic levels where the 9MFYE2023 earnings have far exceeded FYE2017, FYE 2018 and also FYE2019 full year earnings.

Commenting on the results, Tomei managing director Datuk Ng Yih Pyng said, “We preserve our approach to continue focusing on introducing new jewellery designs to the market, as well as expanding our retail outlet network to reach out to various target market of customers. Delivering profitability and enhancing our shareholders’ value remain as the Group’s top priorities. In this regard, we are grateful that we are still able to maintain steady and better earnings, as compared to the pre-pandemic level, notwithstanding the current challenging retail environment.”

He further added, “Our performance is a testament of our resilient and sustainable business strategies, and going forward, we are optimistic that we can continue to achieve positive earnings. I am looking forward to our full year results, of which I am confident will meet Tomei’s expectations.”

As of Sept30, 2023, Tomei has 57 stores across Malaysia.

STAY AHEAD OF THE CURVE

Join our community for instant updates and exclusive content.

Join Telegram Channel

Related


spot_img

Latest News

Addressing medical inflation

Consumers are struggling as medical insurance premiums surge, with over 340,000 dropping coverage amid calls for price regulation and stronger public healthcare

Bora Pharmaceuticals Completes Acquisition of MacroGenics’ Rockville Manufacturing Operations

TAIPEI, TAIWAN - Media OutReach Newswire - 2 July 2026 - Bora Pharmaceuticals Co., Ltd. ("Bora" or "Bora Group"; TWSE: 6472; OTCQX: BORAY) today announced the completion of its acquisition of the GMP manufacturing operations of MacroGenics, Inc. (NASDAQ: MGNX) including its biologics drug substance facility in Rockville, Maryland and an associated warehousing center in Frederick, Maryland, for total consideration of US $122.5 million through its wholly owned subsidiary Bora Biologics USA, LLC.. Upon closing, Bora signed a long-term CDMO Service Agreement with MacroGenics.

Most Viewed

spot_img
WC26

World Cup 2026

Updates, Fixtures, Results & Standings